Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Schaeffer

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
Alimentary Pharmacology & Therapeutics|March 18, 2021
An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trialsRocio Sedano, Christopher Ma, Rish K Pai, et al.
Cell Reports|October 13, 2021
Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasmsKevin C Yang, Steve E Kalloger, John J Aird, et al.
Cell Reports|February 19, 2026
Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasmsKevin C Yang, Steve E Kalloger, John J Aird, et al.
Alimentary Pharmacology & Therapeutics|January 7, 2021
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trialsAhmed Almradi, Christopher Ma, Geert R D'Haens, et al.
Cold Spring Harbor Molecular Case Studies|November 3, 2017
Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencingHui-Li Wong, Kevin C Yang, Yaoqing Shen, et al.
Nature Communications|August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
Nature Communications|March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, James T Topham, Jonathan M Loree, et al.
Cell Metabolism|November 1, 2023
Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammationAnni M Y Zhang, Yi Han Xia, Jeffrey S H Lin, et al.
Cancer Medicine|April 8, 2020
Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screeningCarol Cremin, Michael Kuan-Ching Lee, Quan Hong, et al.
Gastroenterology|February 21, 2021
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical TrialsChristopher Ma, Rocio Sedano, Ahmed Almradi, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Alimentary Pharmacology & Therapeutics|March 18, 2021
An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trialsRocio Sedano, Christopher Ma, Rish K Pai, et al.
Cell Reports|October 13, 2021
Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasmsKevin C Yang, Steve E Kalloger, John J Aird, et al.
Cell Reports|February 19, 2026
Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasmsKevin C Yang, Steve E Kalloger, John J Aird, et al.
Alimentary Pharmacology & Therapeutics|January 7, 2021
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trialsAhmed Almradi, Christopher Ma, Geert R D'Haens, et al.
Cold Spring Harbor Molecular Case Studies|November 3, 2017
Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencingHui-Li Wong, Kevin C Yang, Yaoqing Shen, et al.
Nature Communications|August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
Nature Communications|March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, James T Topham, Jonathan M Loree, et al.
Cell Metabolism|November 1, 2023
Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammationAnni M Y Zhang, Yi Han Xia, Jeffrey S H Lin, et al.
Cancer Medicine|April 8, 2020
Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screeningCarol Cremin, Michael Kuan-Ching Lee, Quan Hong, et al.
Gastroenterology|February 21, 2021
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical TrialsChristopher Ma, Rocio Sedano, Ahmed Almradi, et al.
Pageof 18